Recurrence characteristics in European patients with ocular toxoplasmosis.
BACKGROUND
The risk of function loss after each episode of ocular toxoplasmosis (OT) supports efforts to improve our understanding of the disease.


METHODS
139 patients with OT were contacted retrospectively and requested to complete a questionnaire addressing course and activity of their disease. This information was compared with that retrieved from their medical records. Sixty-three patients completed the questionnaire and were included in the study. They were allocated according to their median age to one of two groups (group 1: <20.9 years; group 2: >or=20.9 years).


RESULTS
The mean reported age at the time of first ocular manifestation was 23.9 (median 20.9, range 0 to 70.5; SD 12.9) years. The clinical diagnosis was made 3.5 years later (p = 0.0008). The follow-up time was 6.5 (median 5.0; range 0.5 to 49.9; SD 7.6) years. The recurrence rate was higher in patients below 20.9 years (66%; n = 35) than in older patients (39%; n = 28; chi(2) test, p<0.05). Patients reporting only one episode were older at first manifestation (29.6 (median 25.6; range 10.6 to 70.5; SD 14.3) years; n = 29) than those reporting two episodes (17.9 (median 19.5; range 5.9 to 33.9; SD 7.8) years; n = 15 (p<0.05)). The proportion of patients who developed a recurrence was 54-63% after each episode without a tendency to enlarge, and the interval between successive episodes remained stable between 1.0 and 1.7 years for the first three recurrences.


CONCLUSIONS
Younger OT patients carry a higher risk of developing a recurrence than older ones. After each episode, two-thirds of all OT patients will develop another one.
Garweg
J G
JG
Swiss Eye Institute, Clinic for Vitreoretinal Disease, Bern, Switzerland. justus.garweg@swiss-eye-institute.com
Scherrer
J N
JN
Halberstadt
M
M
D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000818:Animals; D000913:Antibodies, Protozoan; D000977:Antiparasitic Agents / Q000008:administration & dosage; D018450:Disease Progression; D004812:Epidemiologic Methods; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D012008:Recurrence; D014122:Toxoplasma / Q000276:immunology; D014126:Toxoplasmosis, Ocular / Q000188:drug therapy / Q000453:epidemiology*; D016896:Treatment Outcome
D000913:Antibodies, Protozoan; D000977:Antiparasitic Agents